---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000045"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-07-01T20:11:51+00:00"
generated_at: "2026-07-01T20:13:23.929763+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Rigel Pharmaceuticals appoints Alison Hannah as EVP, CMO; Lisa Rojkjaer departs

## Summary
- Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.
- Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served as a board member since May 2021.
- Lisa Rojkjaer, M.D. ceased as EVP and CMO and separated from the company effective June 25, 2026.
- Dr. Hannah previously served as CMO of CytomX Therapeutics and as a consultant to the pharmaceutical and biotechnology industry.

## SEC filing metadata
- accession: 0001034842-26-000045
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-07-01T20:11:51+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/rigl-20260625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000045
- JSON: https://secwatch.observer/filing/0001034842-26-000045.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000045.txt

## Key facts
- Executive change
  Alison L. Hannah resigned as Director at RIGEL PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Director
  source text: In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm
- Executive change
  Alison L. Hannah was appointed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Executive Vice President and Chief Medical Officer
  source text: On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm
- Executive change
  Lisa Rojkjaer departed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.
  - Action: ceased serving
  - Role: Executive Vice President and Chief Medical Officer
  source text: Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/0001034842-26-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.